This HTML5 document contains 89 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00480/identifier/pharmgkb/
n31http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n26http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00480/identifier/bindingdb/
n22http://linked.opendata.cz/resource/drugbank/dosage/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00480/identifier/pubchem-compound/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00480/identifier/pubchem-substance/
n15http://www.rxlist.com/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00480/identifier/kegg-drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00480/identifier/drugbank/
n14http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00480/identifier/national-drug-code-directory/
n12http://linked.opendata.cz/resource/drugbank/patent/
n29http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n30http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00480/identifier/chemspider/
n25http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n11http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00480/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n27http://linked.opendata.cz/ontology/sukl/drug/
n28http://linked.opendata.cz/resource/atc/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00480/identifier/wikipedia/

Statements

Subject Item
n2:DB00480
rdf:type
n3:Drug
n3:description
Lenalidomide (initially known as CC-5013 and marketed as Revlimid® by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. [Wikipedia] FDA approved on December 27, 2005.
n3:dosage
n22:271B5ADA-363D-11E5-9242-09173F13E4C5 n22:271B5ADB-363D-11E5-9242-09173F13E4C5 n22:271B5ADC-363D-11E5-9242-09173F13E4C5 n22:271B5ADD-363D-11E5-9242-09173F13E4C5 n22:271B5ADE-363D-11E5-9242-09173F13E4C5 n22:271B5AD9-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, Rimsza L, Heaton R, Knight R, Zeldis JB: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005 Feb 10;352(6):549-57. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15703420 # Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV: Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006 Jul 15;108(2):618-21. Epub 2006 Mar 28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16569772 # Anderson KC: Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol. 2005 Oct;42(4 Suppl 4):S3-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16344099
n3:group
approved
n3:halfLife
Healthy subjects = 3 hours; Multiple myeloma or MDS patients = 3 - 5 hours.
n3:indication
Lenalidomide is indicated for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of patients with transfusion-dependent anemia due to low- or intermediate- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.
n3:manufacturer
n4:271B5AD4-363D-11E5-9242-09173F13E4C5 n4:271B5AD3-363D-11E5-9242-09173F13E4C5
owl:sameAs
n14:DB00480 n29:DB00480
dcterms:title
Lenalidomide
adms:identifier
n7:PA162363968 n8:Lenalidomide n9:63791 n16:50078323 n17:187515 n18:46505725 n19:59572-410-00 n20:216326 n21:DB00480 n23:D04687
n3:mechanismOfAction
The mechanism of action of lenalidomide remains to be fully characterized, however it has been demonstrated that lenalidomide inhibits the expression of cyclooxygenase-2 (COX-2), but not COX-1, in vitro. In vivo it induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity
n3:packager
n4:271B5AD2-363D-11E5-9242-09173F13E4C5 n4:271B5AD0-363D-11E5-9242-09173F13E4C5 n4:271B5AD1-363D-11E5-9242-09173F13E4C5
n3:patent
n12:6281230 n12:2342974 n12:7465800 n12:2477301
n3:routeOfElimination
Elimination is primarily renal. When a single oral dose of 25 mg is given healthy subjects, 90% and 4% of the dose is eliminated in urine and feces, respectively. Hydroxy-lenalidomide and N-acetyl-lenalidomide represent 4.59% and 1.83% of the excreted dose, respectively.
n3:synonym
Revlimid CC-5013 CDC 501 IMid-1 1-oxo-2-(2,6-Dioxopiperidin-3-yl)-4-aminoisoindoline 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione IMiD3
n3:toxicity
The most frequently reported adverse events were related to blood and lymphatic system disorders, skin and subcutaneous tissue disorders, gastrointestinal disorders, and general disorders and administrative site conditions.
n27:hasAHFSCode
n31:10-00%20
n3:foodInteraction
When given with a fatty meal, the extent of absorption is reduced.
n3:proteinBinding
30% protein bound.
n3:synthesisReference
Surya Narayana Devarakonda, Sesha Reddy Yarraguntla, Vamsi Krishna Mudapaka, Rajasekhar Kadaboina, Veerender Murki, Amarendhar Manda, Venkata Rao Badisa, Naresh Vemula, Rama Seshagiri Rao Pulla, Venu Nalivela, "PREPARATION OF LENALIDOMIDE." U.S. Patent US20110021567, issued January 27, 2011.
n25:hasConcept
n26:M0479831
foaf:page
n11:lenalidomide.html n15:revlimid-drug.htm
n3:IUPAC-Name
n5:271B5AE3-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B5AE9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B5AE8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B5AE5-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B5AE6-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B5AE7-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B5AE1-363D-11E5-9242-09173F13E4C5 n5:271B5AF9-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B5AE2-363D-11E5-9242-09173F13E4C5 n5:271B5ADF-363D-11E5-9242-09173F13E4C5 n5:271B5AFA-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B5AE0-363D-11E5-9242-09173F13E4C5
n27:hasATCCode
n28:L04AX04
n3:H-Bond-Acceptor-Count
n5:271B5AEF-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B5AF0-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B5AEA-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B5AEB-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B5AED-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B5AEC-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B5AEE-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly absorbed following oral administration, with maximum plasma concentrations occurring between 0.625 and 1.5 hours post-dose. Co-administration with food does not alter the extent of absorption (AUC) but does reduce the maximal plasma concentration (C<sub>max</sub>) by 36%. The pharmacokinetic disposition of lenalidomide is linear. Accumulation does not occur following multiple doses.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
191732-72-6
n3:category
n3:clearance
The renal clearance of lenalidomide exceeds the glomerular filtration rate.
n3:containedIn
n30:271B5AD5-363D-11E5-9242-09173F13E4C5 n30:271B5AD6-363D-11E5-9242-09173F13E4C5 n30:271B5AD7-363D-11E5-9242-09173F13E4C5 n30:271B5AD8-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B5AF5-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B5AF7-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B5AF8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B5AF4-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B5AF3-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B5AF6-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B5AE4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B5AF1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B5AF2-363D-11E5-9242-09173F13E4C5